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Abstract 23 
The COVID-19 pandemic presents an urgent health crisis. Human neutralizing antibodies 24 
(hNAbs) that target the host ACE2 receptor-binding domain (RBD) of the SARS-CoV-2 spike1-5 25 
show therapeutic promise and are being evaluated clincally6-8. To determine structural 26 
correlates of SARS-CoV-2 neutralization, we solved 8 new structures of distinct COVID-19 27 
hNAbs5 in complex with SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed 28 
classification into categories: (1) VH3-53 hNAbs with short CDRH3s that block ACE2 and bind 29 
only to “up” RBDs, (2) ACE2-blocking hNAbs that bind both “up” and “down” RBDs and can 30 
contact adjacent RBDs, (3) hNAbs that bind outside the ACE2 site and recognize “up” and 31 
“down” RBDs, and (4) Previously-described antibodies that do not block ACE2 and bind only 32 
“up” RBDs9. Class 2 comprised four hNAbs whose epitopes bridged RBDs, including a VH3-53 33 
hNAb that used a long CDRH3 with a hydrophobic tip to bridge between adjacent “down” RBDs, 34 
thereby locking spike into a closed conformation. Epitope/paratope mapping revealed few 35 
interactions with host-derived N-glycans and minor contributions of antibody somatic 36 
hypermutations to epitope contacts. Affinity measurements and mapping of naturally-occurring 37 
and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 38 
escape from antibodies elicited during infection or delivered therapeutically. These 39 
classifications and structural analyses provide rules for assigning current and future human 40 
RBD-targeting antibodies into classes, evaluating avidity effects, suggesting combinations for 41 
clinical use, and providing insight into immune responses against SARS-CoV-2.  42 
 43 
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Neutralizing antibodies (NAbs) against SARS-CoV-2 protect against infection in animal 45 
models1,3,4,10,11 and are being evaluated for prophylaxis and as therapeutics in humans7,8. These 46 
antibodies target the SARS-CoV-2 spike (S) trimer3,5,10,12-17, a viral glycoprotein that mediates 47 
binding to angiotensin-converting enzyme 2 (ACE2) receptor18,19. S trimer comprises three 48 
copies of an S1 subunit containing the receptor-binding domain (RBD) and three copies of S2, 49 
which includes the fusion peptide and transmembrane regions20,21. The RBDs of SARS-CoV-2 50 
and other coronaviruses exhibit flexibility, such that they bind ACE2 only when they are in an 51 
“up” conformation, as compared with the “down” RBD conformation of the closed, prefusion S 52 
trimer20-25.  53 
 54 
Many hNAbs isolated from COVID-19 convalescent donors target the RBD, binding to distinct, 55 
sometimes non-overlapping, epitopes3-5,10,12-14,17. A subset of these antibodies blocks viral entry 56 
by binding to the ACE2-binding site on the RBD6,11,13,15,26,27. A family of recurrent ACE2-blocking 57 
hNAbs is composed of heavy chains (HCs) encoded by the VH3-53 or VH3-66 gene 58 
segment3,12,13,16,17,27-29, a majority of which are known or predicted15,26,28,30,31 to exhibit a common 59 
RBD binding mode resulting from the use of germline-encoded residues within the 60 
complementarity-determining regions 1 and 2 (CDRH1 and CDRH2) and a CDRH3 that is 61 
shorter than the average length (15 amino acids; IMGT32 CDR definition) in human antibodies33. 62 
Other SARS-CoV-2 RBD-binding antibodies are encoded by VH3-305, which have also been 63 
isolated from SARS-CoV-infected donors34, and antibodies with a variety of the other VH gene 64 
segments3,5,10,12-17. 65 
 66 
To classify commonalities and differences among RBD-binding hNAbs isolated from 67 
convalescent COVID-19 individuals5, we solved complexes of hNAbs with stabilized (2P and 6P 68 
versions)35,36 of soluble S trimer and used high-resolution details of the binding orientations of 69 
VH1-2, VH1-46, VH3-30, VH3-53, VH4-34, and VH5-51 and hNAbs to elucidate rules for binding 70 
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by four distinct anti-RBD antibody classes (Supplementary Table 2). The hNAbs chosen for 71 
structures are highly potent, achieving 90% neutralization in pseudotype virus assays at 72 
concentrations ranging from 22-140 ng/mL5, thus our structural analyses and classifications 73 
directly relate to understanding mechanisms of neutralization and potency differences between 74 
hNAbs. 75 
 76 
Class 1: VH3-53/short CDRH3 hNAbs that block ACE2 binding and bind “up” RBDs 77 
We solved Fab and Fab-RBD crystal structures of C102 (Supplementary Table 1), which we 78 
compared to our previous cryo-EM structure of S trimer complexed with the related hNAb 79 
C10526 (Extended Data Fig. 1,2). Both C102 and C105 are VH3-53 hNAbs with short (9 and 12 80 
residues) CDRH3s (Extended Data Fig. 1g) that were isolated from the same donor5. They 81 
share structural similarities with each other and with other VH3-53/short CDRH3 hNAb 82 
structures solved as complexes with RBDs12,30,37,38 (Extended Data Fig. 2a). Importantly, the 83 
C102-RBD structure resembled the analogous portion of the C105-S structure26 (Extended Data 84 
Fig. 2a). These results establish that Fab-RBD structures can reproduce interactions with RBDs 85 
in the context of an S trimer; however, Fab-RBD structures do not reveal the state(s) of the 86 
antibody-bound RBD in the complex (“up” versus “down”) or the potential inter-protomer 87 
contacts by Fabs.  88 
 89 
Since the C105 Fab bound either two or three “up” RBDs on S with no observed interactions 90 
with “down” RBDs or with adjacent RBDs26 (Extended Data Fig. 1f), we used the higher-91 
resolution C102 Fab-RBD structure to deduce a more accurate epitope/paratope than possible 92 
using the C105-S cryo-EM structure with flexible “up” RBDs (Extended Data Fig. 1a-e). Buried 93 
surface area (BSA) calculations showed that the C102 CDRH3 played a relatively minor role in 94 
the paratope: of 1045 Å2 BSA on the antibody (786 Å2 on the HC; 259 Å2 on the light chain; LC), 95 
CDRH3 accounted for only 254 Å2 (Extended Data Fig. 2b). This contrasts with the majority of 96 
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antibodies in which CDRH3 contributes equally or more to the interface with antigen than the 97 
sum of CDRH1 and CDRH2 contributions39. The epitopes on RBD for all available VH3-53/short 98 
CDRH3 hNAbs span the ACE2 binding site15,26,28,30,31 and show common RBD-binding 99 
interactions, represented by the C102 epitope (Extended Data Fig. 1b-e), which buried 1017 Å2 100 
on RBD (Extended Data Fig. 2b). The ACE2-blocking epitope for these hNAbs is sterically 101 
occluded in the RBD “down” conformation (Fig. 1b; Extended Data Fig. 1f); therefore, class 1 102 
hNAbs can only bind to “up” RBDs, as observed in the C105-S structure26, and as previously 103 
discussed, IgGs in this class could crosslink adjacent RBDs within a single trimer to achieve 104 
tighter binding through avidity effects26.  105 
 106 
Class 2: hNAbs that overlap with the ACE2 binding site and recognize both “up” and 107 
“down” RBD conformations 108 
In addition to the recurrent VH3-53 hNAbs with short CDRH3s, a small subset of potently 109 
neutralizing VH3-53 encoded antibodies utilize longer CDRH3s (>15 residues, IMGT definition32, 110 
Extended Data Fig. 1g)5,12. A recent structure of a RBD complexed with a VH3-53/long CDRH3 111 
hNAb (COVA2-39) revealed a different RBD binding mode38, thus confirming predictions that 112 
binding with a C102-like interaction requires a short CDRH326,30. To further elucidate molecular 113 
mechanisms for binding of VH3-53/long CDRH3 hNAbs, we solved a 3.2 Å cryo-EM structure of 114 
C144 (VH3-53/VL2-14; 25-residue CDRH3) bound to a S trimer36 (Extended Data Fig. 3). 115 
Despite the ability of ligand-free stabilized S trimers to adopt “up” RBD conformations36 and 116 
modeling suggesting the C144 binding site would be accessible on “up” RBDs (Fig. 1b), the 117 
C144-S structure revealed three C144 Fabs bound to a completely closed S with three “down” 118 
RBDs (Fig. 1a). The C144 binding mode differs from class 1 hNAbs, whose binding orientation 119 
is incompatible with “down” RBD conformations (Fig. 1b). In addition, the binding orientation 120 
observed for C144 differs from the binding described for COVA2-39, whose RBD epitope is 121 
predicted to be accessible only on “up” RBDs38 due to steric hinderances imposed on the LC by 122 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 30, 2020. . https://doi.org/10.1101/2020.08.30.273920doi: bioRxiv preprint 
 6
the N343RBD-associated glycan on the adjacent RBD (Extended Data Fig. 1h). Despite 123 
orientation differences, the RBD epitopes of C144, C102 and COVA2-39 overlap with the ACE2 124 
binding site, suggesting a neutralization mechanism involving direct competition with ACE2 (Fig. 125 
1b).  40 126 
 127 
An interesting feature of C144 binding is that its long CDRH3 bridges between adjacent “down” 128 
RBDs to lock the spike glycoprotein into a closed, prefusion conformation, providing an 129 
additional neutralization mechanism in which S cannot open to engage ACE2 (Fig. 1c,d). The 130 
formation of C144’s quaternary epitope is driven by sandwiching CDRH3 residues F100D and 131 
W100E into a hydrophobic RBD cavity at the base of an N-linked glycan attached to N343RBD. 132 
The cavity comprises the RBD α1 helix (337-344), α2 helix (364-371), and hydrophobic 133 
residues (F374RBD and W436RBD) at the edge of the RBD 5-stranded β-sheet (Fig. 1e,f). By 134 
contrast to CDRH3s of class 1 VH3-53/short CDRH3 hNAbs, C144’s CDRH3 contributed to a 135 
majority (~60%) of the paratope and buried 330 Å2 surface area on the adjacent RBD (Extended 136 
Data Fig. 2b), likely explaining observed escape at residue L455RBD (Fig. 1f) in C144 selection 137 
experiments40. Despite adjacent hydrophobic residues (F100D and W100E) likely to be solvent-138 
exposed before antigen binding, C144 IgG showed no evidence of non-specific binding in a 139 
polyreactivity assay (Extended Data Fig. 1i). 140 
 141 
Given the unusual binding characteristics of C144, we investigated whether antibodies that 142 
showed similar S binding orientations in low-resolution negative-stain EM (nsEM) 143 
reconstructions5 utilize similar neutralization mechanisms. We characterized Fab-S cryo-EM 144 
structures (overall resolutions from 3.4-3.8 Å) of potent hNAbs (C002, C104, C119, and C121) 145 
predicted to compete with ACE2 binding5, which varied in their V gene segment usage and 146 
CDRH3 lengths (Fig. 2, Extended Data Figs. 3,4; Extended Data Table 1). Fab-S cryo-EM 147 
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structures of these class 2 hNAbs showed bound RBDs in both “up” or “down” conformations, 148 
consistent with observations of similar hNAbs from nsEM5,12 and single-particle cryo-EM 149 
studies10,34,41. By contrast, the C144-S structure showed Fabs bound only to “down” RBDs (Fig. 150 
1), suggesting that C144 binding requires recognition of the closed S trimer, or that C144 Fab(s) 151 
initially bound to “up” RBD(s) could trap the closed (3 RBDs “down”) S conformation through 152 
CDRH3-mediated interactions between adjacent RBDs.  153 
 154 
To better understand commonalities of class 2 RBD epitopes, we further analyzed two 155 
additional potent hNAbs, C002 (VH3-30/VK1-39, 17-residue CDRH3, IC50=8.0 ng/mL5) and 156 
C121 (VH1-2/VL2-23, 23-residue CDRH3, IC50=6.7 ng/mL5), for which cryo-EM Fab-S 157 
structures were solved to 3.4 Å and 3.6 Å, respectively (Fig. 2a,b) using crystal structures of 158 
unbound C002 and C121 Fabs for fitting (Supplementary Table 1). The C002 and C121 RBD 159 
epitopes are focused on the receptor-binding ridge, overlapping with polar and hydrophobic 160 
residues along the flat face of the RBD responsible for ACE2 interactions (Fig. 2c-e). Similar to 161 
C144, hNAbs C002 and C121 buried most of the RBD epitope against HC CDR loops, with LC 162 
CDR loops engaging the receptor-binding ridge (Fig. 3). Interestingly, Fab-S structures of C002, 163 
C121, C119 and C104 revealed a quaternary epitope involving an adjacent RBD (Extended 164 
Data Figs. 3,4, 5a-c), albeit distinct from the quaternary binding of C144 (Fig. 1c-e). This 165 
C102/C121/C119/C104 type of secondary interaction was only observed when a Fab was 166 
bound to a “down” RBD and adjacent to an “up” RBD. The extent of the secondary interactions 167 
varied depending on the antibody pose (Extended Data Fig. 5a-c). Bridging interactions 168 
between adjacent “up” and “down” RBDs would not allow the two Fabs of a single IgG to bind 169 
simultaneously to an S trimer. However, this class of antibodies could support bivalent 170 
interactions between two adjacent “down” RBDs (Extended Data Fig. 5h, Extended Data Table 171 
1). 172 
 173 
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 Characterization of the highest resolution interface (C002-S structure) showed C002 LC 174 
framework regions (FWRs) 1 and 2 interfaced with the RBD residues comprising the 5-stranded 175 
β-sheet and α-helix that spans residues 440RBD–444RBD (Fig. 2e), which is typically located near 176 
the three-fold axis of a closed S trimer. In addition to contacting neighboring RBDs, inter-177 
protomer engagement with the N165NTD-associated glycan in the N-terminal domain (NTD) was 178 
observed for the class 2 hNAb BD2313. If fully processed, the N165NTD glycan could adopt a 179 
conformation that would allow interactions with HC FWR3 and CDRH1 (Fig. 2e). However, in 180 
the structures reported here, we did not observe N165RBD glycan density beyond the initial 181 
GlcNAc. 182 
 183 
Given differences in class 2 hNAb V gene segments, CDRH3 lengths, and antibody poses, we 184 
investigated sequence features that drive conserved interactions. Sequence differences 185 
between SARS-CoV-2 and SARS-CoV RBD, including at positions 486RBD and 493RBD (F and Q, 186 
respectively, in SARS-CoV-2), in the ACE2 receptor-binding motif (RBM) allowed more 187 
favorable ACE2 binding to the SARS-CoV-2 RBD42. Analysis of interactions by C144, C002, and 188 
C121 revealed common interactions with these residues and also for E484RBD by both antibody 189 
HC and LC residues (Fig. 3). In particular, class 2 hNAb interactions with F486RBD mimicked 190 
ACE2 interactions, in that F486RBD buries into a hydrophobic pocket typically involving 191 
CDRL1/CDRL3 tyrosine residues43 (Fig. 3d,h,l). Mimicking of the ACE2 F486RBD binding pocket 192 
by SARS-CoV-2 hNAbs was observed across different LC V gene segments (Extended Data 193 
Table 1), suggesting that there is no restriction in LC V gene segment usage for class 2 hNAbs. 194 
Interestingly, a germline-encoded feature described for VH3-53/short CDRH3 class 1 hNAbs, 195 
the CDRH2 SxxS motif, is also found in other class 2 hNAbs (e.g., C121 and C119) despite 196 
different VH gene segment usage. Similar to VH3-53 hNAbs C144 and COVA2-39, the C121 197 
CDRH2 SxxS motif forms a potential hydrogen bond network with residue E484RBD (Fig. 3b,j).  198 
 199 
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Overall, these results suggest a convergent mode of recognition by germline-encoded residues 200 
across diverse VH/VL gene segments for SARS-CoV-2, which may contribute to low levels of 201 
somatic hypermutation observed for these hNAbs (Extended Data Fig. 6, Extended Data Table 202 
1). 203 
 204 
Class 3: hNAbs that bind outside the ACE2 binding site and recognize both “up” and 205 
“down” RBD conformations 206 
C135 is a potent hNAb that showed binding properties distinct from class 1, class 2, and the 207 
cross-reactive SARS-CoV antibody CR30225 (which we categorized as a class 4 antibody; 208 
Extended Data Table 1). To evaluate the mechanism of C135-mediated neutralization of SARS-209 
CoV-2, we solved the cryo-EM structure of a C135-S complex to 3.5 Å (Fig. 4a, Extended Data 210 
Fig. 7), using an unbound C135 crystal structure for fitting (Supplementary Table 1). The 211 
structure revealed three C135 Fabs bound to an S trimer with 2 “down” and 1 “up” RBDs, 212 
although the C135-bound “up” RBD conformation was weakly resolved and therefore not 213 
modeled. C135 recognizes an glycopeptidic epitope similar to the cross-reactive SARS-CoV 214 
hNAb S30934, focusing on a region of the RBD near the N343RBD glycan and non-overlapping 215 
with the ACE2 binding site (Fig. 4b, Extended Data Fig. 7c,d). Despite differences in binding 216 
orientations between C135 and S309, targeting of the RBD epitope was mainly VH-mediated 217 
(the BSA of RBD on the C135 HC represented ~480Å2 of ~700 Å2 total BSA) and included 218 
interactions with the core fucose moiety of the N343RBD glycan. The smaller C135 footprint 219 
relative to S309 (~700 Å2 versus ~1150 Å2 BSA, respectively; Extended Data Fig. 7c,d) focused 220 
on interactions with RBD residues R346RBD and N440RBD, which are engaged by residues from 221 
HC and LC CDR loops (Fig. 4c,d) and are not conserved between SARS-CoV-2 and SARS-CoV 222 
RBDs, rationalizing the lack of SARS-CoV cross-reactivity observed for C1355.  223 
 224 
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The discovery of class 3 hNAbs such as C135 and S309 that were raised during SARS-CoV-2 225 
or SARS-CoV natural infections, respectively, and bind outside of the ACE2 binding site, 226 
provides the potential for additive neutralization effects when combined with hNAbs that block 227 
ACE2, while also limiting viral escape1,40. A pair of antibodies in human clinical trials that 228 
includes REGN109878, a hNAb that binds distal to the ACE2 binding site, prevented SARS-229 
CoV-2 viral escape in vitro, but did not show synergistic neutralization6. Comparison of C135 230 
and REGN10987 interactions with S showed similarities in epitopes (interactions focused on 231 
residues R346RBD and N440RBD; Extended Fig. 7c,f). However, REGN10987 binding would 232 
sterically hinder ACE2 interactions, whereas C135 binding does not (Extended Data Fig. 7b, 233 
Fig. 4b). Interestingly, a structure of S complexed with C110 (VH5-51/VK1-5), isolated from the 234 
same donor as the C102 and C105 (class 1) and C119 and C121 (class 2) hNAbs5, showed a 235 
binding pose resembling REGN10987’s (Extended Data Fig. 7b,e-f). The C110 epitope showed 236 
similarities with both class 3 and class 2 hNAbs, binding distal to the ACE2 binding motif, but 237 
like REGN10987, could potentially sterically interfere with ACE2 (Extended Fig. 7). For each of 238 
these class 3 hNAbs, the Fab binding pose suggests that intra-protomer crosslinking by a single 239 
IgG is not possible (Extended Data Table 1). 240 
 241 
Class 3 hNAbs add to the anti-SARS-CoV-2 antibody repertoire and could likely be effectively 242 
used in therapeutic combinations with class 1 or class 2 hNAbs. However, when using 243 
structures to predict whether hNAbs have overlapping epitopes, it is sometimes not sufficient to 244 
only examine Fab-RBD structures or even static images of S trimer because of the dynamic 245 
nature of the spike. Thus what might appear to be non-overlapping epitopes on an isolated RBD 246 
could overlap in some (Fig, 4e,f), but not all (Extended Data Fig. 8), scenarios on a spike trimer, 247 
complicating interpretation of competition experiments using monomeric RBDs and S trimers. 248 
The opposite can also be true; i.e., two Fabs that are predicted to be accommodated on a trimer 249 
could clash on an RBD monomer (Fig. 4g,h). Finally, adjacent monomers in different 250 
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orientations could accommodate different antibodies that target overlapping sites (Extended 251 
Data Fig. 8). 252 
 253 
RBD substitutions affect hNAb binding to varying extents 254 
VSV reporter viruses pseudotyped with SARS-CoV-2 S can escape by mutation from hNAbs 255 
C121, C135, or C14440, three of the antibodies used for the structural studies reported here. 256 
RBD mutations that were selected in response to antibody pressure correlated with the epitopes 257 
mapped from the structures of their Fabs complexed with S trimer (Fig. 1,2,4).  258 
 259 
To further assess the effects of these and other RBD substitutions, we assayed hNAbs for 260 
which we obtained structural information (eight from this study; C105-S complex from ref.26) for 261 
binding to mutated RBD proteins. The RBD mutants included two that induced escape from the 262 
class 3 hNAb C135 (R346S and N440K)40 (Fig. 4c,d), one found in circulating isolates44 that 263 
conferred partial resistance to C135 (N439K)40 (Fig. 4d), a circulating variant (A475V) that 264 
conferred resistance to class 1 and 2 VH3-53 hNAbs44, two that induced escape from C121 or 265 
C144 (E484K and Q493R)40 (Fig. 3), and a circulating variant that conferred partial resistance to 266 
C121 (V483A)40. Kinetic and equilibrium constants for the original and mutant RBDs were 267 
derived from surface plasmon resonance (SPR) binding assays in which RBDs were injected 268 
over immobilized IgGs (Extended Data Fig. 9). Loss of binding affinity was consistent with RBD 269 
mutations that conferred escape, with hNAbs within each class being similarly affected by the 270 
same point mutations, which was not seen when comparing effects of point mutations between 271 
hNAb classes. This suggests that antibody pressure that leads to escape from one hNAb class 272 
would be unlikely to affect a different class. These results suggest a therapeutic strategy 273 
involving hNAbs of different classes for monoclonal NAb treatment of SARS-CoV-2–infected 274 
individuals. 275 
 276 
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Conclusions 277 
The Fab-S structures reported here represent a comprehensive structural, biophysical, and 278 
bioinformatics analysis of SARS-CoV-2 NAbs (Extended Data Fig. 10), providing critical 279 
information for interpreting correlates of protection for clinical use. The structures reveal a 280 
wealth of unexpected interactions of hNAbs with the spike trimer, including five antibodies that 281 
reach between adjacent RBDs on the protomers of a single spike trimer. A dramatic example of 282 
bridging between spike protomers involved a hNAb, C144, that uses a long CDRH3 with a 283 
hydrophobic tip to reach across to an adjacent RBD, resulting in all three RBDs on spike trimer 284 
being locked into a closed conformation. This example, and the four other hNAbs that contact 285 
adjacent RBDs, demonstrates that crystal structures of Fab-monomeric RBD complexes, while 286 
informative for defining a primary epitope on one RBD, do not reveal how antibodies actually 287 
recognize the flexible “up”/”down” RBD conformations on the spike trimer that are targeted for 288 
neutralization on the virus. Indeed, our cryo-EM structures of Fab-spike trimer complexes 289 
showed many possible combinations of recognized RBDs: three “up,” two “up” and one “down,” 290 
one “up” and two “down,” and three “down,” with some structures showing three Fabs bound per 291 
trimer and others showing two Fabs bound per trimer. By analyzing the approach angles of 292 
antibodies bound to RBDs on spike trimers, we can predict whether a particular IgG can bind to 293 
a single spike trimer to gain potency through avidity effects, which would also render the 294 
antibody more resistant to spike mutations. In addition, structural information allowed us to 295 
assess RBD mutants that arose in circulating viral isolates and/or were obtained by in vitro 296 
selection. Taken together, this comprehensive study provides a blueprint for designing antibody 297 
cocktails for therapeutics and potential spike-based immunogens for vaccines. 298 
  299 
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Methods 300 
Protein Expression 301 
Expression and purification of SARS-CoV-2 ectodomains were conducted as previously 302 
described26. Briefly, constructs encoded the SARS-CoV-2 S ectodomain (residues 16-1206 of 303 
the early SARS-CoV-2 GenBank MN985325.1 sequence isolate with 2P35 or 6P36 stabilizing 304 
mutations, a mutated furin cleavage site between S1 and S2, a C-terminal TEV site, foldon 305 
trimerization motif, octa-His tag, and AviTag) were used to express soluble SARS-CoV-2 S 306 
ectodomains. Constructs encoding the SARS-CoV-2 RBD from GenBank MN985325.1  307 
(residues 331-524 with C-terminal octa-His tag and AviTag) and mutant RBDs were made as 308 
described26, SARS-CoV-2 2P S, 6P S, and RBD proteins were purified from the supernatants of 309 
transiently-transfected Expi293F cells (Gibco) by nickel affinity and size-exclusion 310 
chromatography26. Peak fractions were identified by SDS-PAGE, and fractions corresponding to 311 
S trimers or monomeric RBDs were pooled and stored at 4˚C. Fabs and IgGs were expressed, 312 
purified, and stored as described45,46.  313 
 314 
X-ray crystallography 315 
Crystallization trials were carried out at room temperature using the sitting drop vapor diffusion 316 
method by mixing equal volumes of a Fab or Fab-RBD complex and reservoir using a TTP 317 
LabTech Mosquito robot and commercially-available screens (Hampton Research). Crystals 318 
were obtained in 0.2 M ammonium sulfate, 20% w/v PEG 3350 (C102 Fab), 0.2 M sodium 319 
citrate tribasic, 20% w/v PEG 3350 (C102-RBD), 0.2 M lithium sulfate monohydrate, 20% w/v 320 
PEG 3350 (C002 Fab), 0.04 M potassium phosphate, 16% w/v PEG 8000, 20% v/v glycerol 321 
(C135 Fab), 0.2 M ammonium citrate pH 5.1, 20% PEG 3350 (C121 Fab), or 0.2 M sodium 322 
tartrate dibasic dihydrate pH 7.3, 20 % w/v PEG 3350 (C110 Fab). A C135 Fab crystal was 323 
directly looped and cryopreserved in liquid nitrogen. Other crystals were quickly cryoprotected in 324 
a mixture of well solution with 20% glycerol and then cryopreserved in liquid nitrogen. 325 
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 326 
X-ray diffraction data were collected for Fabs and the Fab-RBD complex at the Stanford 327 
Synchrotron Radiation Lightsource (SSRL) beamline 12-1 on a Pilatus 6M pixel detector 328 
(Dectris) at a wavelength of 1.0 Å. Data from single crystals of C121 Fab and C110 Fab were 329 
indexed and integrated in XDS47 and merged using AIMLESS in CCP448 (Supplementary Table 330 
1). Data from single crystals of C102 Fab, C135 Fab, and C002 fab were indexed and 331 
integrated using XDS47 and merged in Phenix49. Diffraction data for C002 Fab were 332 
anisotropically truncated and scaled using the UCLA Anisotropy Server50 prior to merging. Data 333 
from a single crystal of C102 Fab-RBD complex were indexed and integrated using XIA251 334 
implementing DIALS52,53 and merged using AIMLESS in CCP448. For C110 Fab and C121 Fabs, 335 
structures were determined by molecular replacement in PHASER54 using the coordinates for 336 
B38 (PDB 7BZ5) or an inferred germline form of the HIV-1 NAb IOMA55 inferred germline 337 
(unpublished), respectively, after removing CDR loops as a search model. For C002 Fab, C102 338 
Fab, C102 Fab-RBD, and C135 Fab, structures were determined by molecular replacement in 339 
PHASER54 using B38 Fab coordinates (PDB 7BZ5) after trimming HC and LC variable domains 340 
using Sculptor56 (and for the C102 Fab-RBD data, also RBD coordinates from PDB 7BZ5) as 341 
search models. Coordinates were refined using Phenix49 and cycles of manual building in Coot57 342 
(Supplementary Table 1). 343 
 344 
Cryo-EM Sample Preparation 345 
Purified Fabs were mixed with SARS-CoV-2 S 2P trimer35 or SARS-CoV-2 S 6P trimer36 (1.1:1 346 
molar ratio Fab per protomer) to a final Fab-S complex concentration of 2-3 mg/mL and 347 
incubated on ice for 30 minutes. Immediately before deposition of 3 μL of complex onto a 300 348 
mesh, 1.2/1.3 AuUltraFoil grid (Electron Microscopy Sciences) that had been freshly glow-349 
discharged for 1 min at 20 mA using a PELCO easiGLOW (Ted Pella), a 0.5% w/v octyl-350 
maltoside, fluorinated solution (Anatrace) was added to each sample to a final concentration of 351 
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0.02%. Samples were vitrified in 100% liquid ethane using a Mark IV Vitrobot (Thermo Fisher) 352 
after blotting at 22°C and 100% humidity for 3 s with Whatman No. 1 filter paper. 353 
 354 
Cryo-EM Data Collection and Processing 355 
Single-particle cryo-EM data were collected on a Titan Krios transmission electron microscope 356 
(Thermo Fisher) operating at 300 kV for all Fab-S complexes except for C144-S, which was 357 
collected on a Talos Arctica (Thermo Fisher) operating at 200 kV. Movies were collected using 358 
SerialEM automated data collection software58 with beam-image shift over a 3 by 3 pattern of 359 
1.2 µm holes with 1 exposure per hole. Movies were recorded in super-resolution mode on a K3 360 
camera (Gatan) for the C144-S dataset on the Arctica (0.435 Å/pixel) or on a K3 behind 361 
BioQuantum energy filter (Gatan) with a 20 eV slit on the Krios (0.418 Å/pixel) for all other 362 
datasets. Data collections parameters are summarized in Supplementary Table 2. In general, 363 
the data processing workflow described below was performed for all data sets in cryoSPARC 364 
v2.1559. 365 
 366 
Cryo-EM movies were patch motion corrected for beam-induced motion including dose 367 
weighting within cryoSPARC59 after binning super-resolution movies. The non-dose-weighted 368 
images were used to estimate CTF parameters using CTFFIND460 or with cryoSPARC 369 
implementation of the Patch CTF job, and micrographs with power spectra that showed poor 370 
CTF fits or signs of crystalline ice were discarded. A subset of images were randomly selected 371 
and used for reference-free particle picking using Blob picker in cryoSPARC59. Particles were 372 
subjected to 2D classification and the best class averages that represented different views were 373 
used to generate 3 ab initio models. The particles from the best classes were used in another 374 
2D classification job, and the best set of unique views was utilized as templates for particle 375 
picking on the full set of images. Initial particle stacks were extracted, down-sampled x2, and 376 
used in heterogeneous refinement against the 3 ab initio volumes generated with the smaller 377 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 30, 2020. . https://doi.org/10.1101/2020.08.30.273920doi: bioRxiv preprint 
 16
dataset (ab initio volumes used were interpreted as a Fab-S complex, free Fab or dissociated S 378 
protomers, and junk/noise class). Particles assigned to the Fab-S volume were further cleaned 379 
via iterative rounds of 2D classification to select class averages that displayed unique views and 380 
secondary structural elements. Resulting particle stacks were homogenously refined before 381 
being split into 9 individual exposure groups based upon collection holes. Per particle CTF and 382 
aberration corrections were performed and the resulting particles further 3D refined. Additional 383 
processing details are summarized in Supplementary Table 2.  384 
 385 
Given the known heterogeneity of spike trimers20,21, homogenously refined particles were used 386 
for 3D classification in cryoSPARC59 (ab initio job: k=4 classes, class similarity=0.3). This 387 
typically resulted in one or two majority Fab-S complexes, with the other minority populated 388 
classes representing junk or unbound S trimer. Particles from the good class(es) were further 389 
subjected to 3D classification (ab initio job: k=4, class similarity=0.7) to attempt to separate 390 
various Fab-S complex states. If multiple states were identified (as observed for C002-S and 391 
C121-S complexes), particles were heterogeneously refined, followed by re-extraction without 392 
binning (0.836Å/pixel) before homogeneous refinement of individual states. For all other 393 
datasets, the majority of particles represented one state that was homogenously refined after re-394 
extraction without binning.  395 
 396 
Particle stacks for individual states were non-uniform refined with C1 symmetry and a dynamic 397 
mask. To improve resolution at the Fab-RBD interfaces, volumes were segmented in Chimera61 398 
and the regions corresponding to the NTDS1/RBDS1 domains and Fab VH-VL domains were 399 
extracted and used to generate a soft mask (5-pixel extension, 10-pixel soft cosine edge). Local 400 
refinements with the mask resulted in modest improvements of the Fab-RBD interface, which 401 
allowed for fitting and refinement of this region. The particles were then subjected to CTF 402 
refinement and aberration correction, followed by a focused, non-uniform refinement with 403 
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polished particles imposing C1 symmetry (except for the C144-S complex where C3 symmetry 404 
was utilized). Final overall resolutions were according to the gold-standard FSC62. Details of 405 
overall resolution and locally-refined resolutions according to the gold-standard FSC62 can be 406 
found in Supplementary Table 2. 407 
 408 
Cryo-EM Structure Modeling and Refinement 409 
Coordinates for initial complexes were generated by docking individual chains from reference 410 
structures into cryo-EM density using UCSF Chimera63. The following coordinates were used: 411 
SARS-CoV-2 S trimers: PDBs 6VYB and 6XKL, “up” RBD conformations: PDB 7BZ5, unbound 412 
C102, C002, C110, C135 Fab structures (this study) (Supplementary Table 1). Initial models 413 
were then refined into cryo-EM maps using one round of rigid body refinement followed by real 414 
space refinement. Sequence-updated models were built manually in Coot57 and then refined 415 
using iterative rounds of refinement in Coot57 and Phenix49. Glycans were modeled at potential 416 
N-linked glycosylation sites (PNGSs) in Coot57 using ‘blurred’ maps processed with a variety of 417 
B-factors64. Validation of model coordinates was performed using MolProbity65 (Supplementary 418 
Table 2). 419 
 420 
Structural Analyses 421 
CDR lengths were calculated based on IMGT definitions32. Structure figures were made with 422 
PyMOL (Version 1.8.2.1 Schrodinger, LLC) or UCSF ChimeraX61. Local resolution maps were 423 
calculated using cryoSPARC v 2.1559. Buried surface areas were calculated using PDBePISA66 424 
and a 1.4 Å probe. Potential hydrogen bonds were assigned as interactions that were <4.0Å 425 
and with A-D-H angle >90˚. Potential van der Waals interactions between atoms were assigned 426 
as interactions that were <4.0Å. Hydrogen bond and van der Waals interaction assignments are 427 
tentative due to resolution limitations. RMSD calculations following pairwise Cα alignments were 428 
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done in PyMOL without rejecting outliers. Criteria for epitope assignments are described in 429 
figure legends. 430 
 431 
To evaluate whether intra-spike crosslinking by an IgG binding to a single spike trimer was 432 
possible (Extended Data Table 1), we first measured the Cα distance between a pair of 433 
residues near the C-termini of adjacent Fab CH1 domains (residue 222HC on each Fab) 434 
(Extended Data Fig. 5h). We compared this distance to the analogous distances in crystal 435 
structures of intact IgGs (42 Å, PDB 1HZH; 48 Å, PDB 1IGY; 52 Å, PDB 1IGT). To account for 436 
potential influences of crystal packing in these measurements, as well as flexibility in the VH-437 
VL/CH1-CL elbow bend angle and uncertainties in CH1-CL domain placement in Fab-S cryo-EM 438 
structures, we set a cut-off of ≤65 Å for this measured distance as possibly allowing for a single 439 
IgG to include both Fabs. Entries in the “Potential IgG intra-spike binding” column in Extended 440 
Data Table 1 are marked “No” if all of the adjacent Fabs in cryo-EM classes of that structure are 441 
separated by >65 Å for this measured distance. Entries in the “Potential IgG intra-spike binding” 442 
column in Extended Data Table 1 are marked as “Yes” if at least one pair of the adjacent Fabs 443 
in cryo-EM classes of that structure are separated by ≤65 Å for this measured distance. 444 
 445 
Surface plasmon resonance (SPR) binding experiments 446 
SPR experiments were performed using a Biacore T200 instrument (GE Healthcare). IgGs were 447 
immobilized on a CM5 chip by primary amine chemistry (Biacore manual) to a final response 448 
level of ~3000 resonance units (RUs). Concentration series of the original SARS-Cov-2 RBD 449 
and RBD mutants (six 4-fold dilutions starting from a top concentration of 1000 nM) were 450 
injected at a flow rate of at a flow rate of 30 μL/min over immobilized IgGs for a contact time of 451 
60 sec, followed by a injection of 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v 452 
surfactant P20 buffer for a dissociation time of 300 sec. Binding reactions were allowed to reach 453 
equilibrium, and KDs were calculated from the ratio of association and dissociation rates (KD = 454 
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kd/ka) derived from a 1:1 binding model (C002, C102, C105, C110, and C119 (except for C119-455 
E484K), C121, C135, and C144), or from a two-state binding model (KD = kd1/ka1 × 456 
kd2/[kd2+ka2]) (C104, C119-E484K). Kinetic constants were calculated using Biacore T200 457 
Evaluation Software v3.2 using a global fit to all curves in each data set. Flow cells were 458 
regenerated with 10 mM glycine pH 2.0 at a flow rate of 90 μL/min.  459 
 460 
Polyreactivity assays 461 
IgGs were evaluated for off-target interactions by measuring binding to baculovirus extracts 462 
containing non-specific proteins and lipids as described60. The assays were automated on a 463 
Tecan Evo2 liquid handling robot fitted with a Tecan Infinite M1000 plate reader capable of 464 
reading luminescence. Maxisorb 384-well plates (Nunc) were adsorbed overnight with a 1% 465 
preparation of recombinant baculovirus particles generated in Sf9 insect cells67. The adsorbed 466 
plate was blocked with 0.5% BSA in PBS, then incubated with 20 µL of a 1.0 µg/mL solution of 467 
IgG in PBS for 3 hours. Polyreactivity was quantified by detecting bound IgG using an HRP-468 
conjugated anti-human IgG secondary antibody (Genscript) and SuperSignal ELISA Femto 469 
Maxiumum Sensitivity Substrate (Thermo Scientific). Relative Light Units (RLU) were measured 470 
at 475 nm in the integrated plate reader. Engineered human anti-HIV-1 IgGs previously 471 
demonstrated to exhibit high levels of polyreactivity (NIH45-46G54W and 45-46m2)61,62 were used 472 
as positive controls. NIH45-46, which exhibited intermediate polyreactivity63, was also evaluated 473 
for comparisons. Negative control IgGs with low polyreactivity included the human HIV-1 474 
antibodies N664 and 3BNC11763 and bovine serum albumin (BSA). RLU values are presented 475 
as the mean and standard deviation of triplicate measurements in Extended Data Fig. 1i. 476 
 477 
Reporting Summary 478 
Further information on research design is available in the Nature Research Reporting Summary 479 
linked to this paper. 480 
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 481 
Data availability 482 
The cryo-EM maps and atomic models will be deposited at the EMDB and the PDB. Crystal 483 
structure data will be deposited in the PDB. Described materials will be available upon request, 484 
in some cases after completion of a materials transfer agreement. 485 
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Figure 1 715 
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Figure 1. Cryo-EM structure of the C144-S complex illustrates a distinct VH3-53 hNAb 720 
binding mode. a, 3.2 Å cryo-EM density for C144-S trimer complex revealing C144 binding to a 721 
closed (3 RBDs “down”) spike conformation. b, Overlay of C102 Fab (from C102-RBD crystal 722 
structure; Extended Data Fig. 1) and C144 Fab (from C144-S structure) aligned on a RBD 723 
monomer. ACE2 (PDB 6M0J; light green surface) is aligned on the same RBD for reference. 724 
C144 adopts a distinct conformation relative to the C102-like VH3-53/short CDRH3 NAb class, 725 
allowing binding to the “down” RBD conformation on trimeric spike, whereas C102-like NAbs 726 
can only bind “up” RBDs. c, Quaternary epitope of C144 involving bridging between adjacent 727 
RBDs via the CDRH3 loop. d,e, Close-up view of CDRH3-mediated contacts on adjacent 728 
protomer RBD (dark gray). C144 CDRH3 residues F100D and W100E are buried in a 729 
hydrophobic pocket comprising the RBD α1 helix, residue F374RBD and the N343RBD-glycan. f, 730 
Surface representation of C144 epitope (light blue) across two adjacent RBDs. RBD epitope 731 
residues (defined as residues containing atom(s) within 4 Å of a Fab atom) are labeled in black. 732 
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Figure 2 734 
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Figure 2. Cryo-EM structures of class 2 C002 and C121 hNAbs show binding to “up” and 738 
“down” RBDs. a,b, Cryo-EM densities for C002-S (panel a; 3.4 Å) and C121-S complexes 739 
(panel b; 3.7 Å) revealing binding of C002 or C121 to both “down” and “up” RBDs. Inset: 740 
Alignment of C002 and C121 Fabs on the same RBD. ACE2 is represented as a green surface 741 
for reference. c,d, Surface representations of C002 epitope (orange, panel c) and C121 epitope 742 
(purple, panel d) on the RBD surface (gray). RBD epitope residues (defined as residues 743 
containing atom(s) within 4 Å of a Fab atom) are labeled in black. e, C002 forms inter-protomer 744 
contacts via binding to an adjacent “up” RBD conformation on the surface of the trimer spike 745 
(also observed for class 2 C121-, C119-, and C104-S structures, see Extended Data Fig. 5). 746 
Red box: Close-up of adjacent “up” RBD and C002 LC interface. 747 
 748 
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Figure 3 750 
 751 
 752 
 753 
 754 
Figure 3. Details of common RBD interactions among class 2 hNAbs. Conserved 755 
interactions between the RBD and CDRs of class 2 NAbs as observed for a-d, C144 (HC: cyan, 756 
LC: sky blue), e-h, C002 (HC: dark orange, LC: light orange), and i-l, C121 (HC: purple, LC: 757 
pink). Primary and secondary epitopes on adjacent “down” RBDs are shown for C144. 758 
Secondary epitopes for C002 and C121, which require adjacent “up” RBDs, are shown in 759 
Extended Data Fig. 5. RBDs are gray; potential H-bonds and pi-pi stacking interactions (panel d, 760 
Y33LC and F486RBD; panel h, Y92LC and F486RBD; panel l, Y91LC and F486RBD) are indicated by 761 
dashed lines.  762 
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Figure 4 764 
 765 
 766 
 767 
Figure 4. Cryo-EM structure of S complexed with the class 3 (non-ACE2 blocking) hNAb 768 
C135. a, 3.5 Å cryo-EM density of C135-S complex. b, Composite model of C135-RBD (blue 769 
and gray, respectively) overlaid with the SARS-CoV-2 NAb S309 (sand, PDB 6WPS) and 770 
soluble ACE2 (green, PDB 6M0J). The model was generated by aligning on 188 RBD 771 
Cα atoms. c-d, C135 CDRH (dark blue) and CDRL (light blue) interactions with residues 772 
R346RBD (panel c) and N440RBD (panel d). Potential pi-pi stacking interactions in c and H-bonds 773 
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in c and d are illustrated by dashed black lines. e-f, Model of RBD interactions of NAbs C135 774 
(class 3) and C144 (class 2) demonstrating that both Fabs can bind simultaneously to a single 775 
monomeric RBD (panel e), but would clash if bound to adjacent “down” RDBs on S trimer (panel 776 
f). Steric clashes indicated by a red and yellow star in f. g-h, Model of RBD interaction of NAbs 777 
C135 (class 3) and C119 (class 2) demonstrating that both Fabs cannot bind simultaneously to 778 
a single monomeric RBD (panel g), but do not clash if bound to adjacent “down” RDBs on S 779 
trimer (panel h). Steric clashes indicated by a red and yellow star in g.  780 
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 782 
Extended Data Table 1. Anti-SARS-CoV-2 NAb classification and structural properties. 783 
 784 
 785 
  786 
Extended Table 1. Classification and structural properties of SARS-CoV-2 RBD-specific antibodies
Antibody Reference
IGHV 
(# of aa 
SHM)
CDRH3 
length 
(aa)^
IGLV 
(# of aa 
SHM)
CDRL3 
length 
(aa)^
IC50/IC90       
(ng/mL)†
Potential 
IgG intra-
spike 
binding§
Contacts
adjacent 
RBD Structural Information
Class 1: Blocks ACE2, accessibility of RBD epitope only in "up" conformation
C102 this study VH3-53  (2) 11 VK3-20  (0) 9 34 / 143 ??? ??? 3.0 Å Fab-RBD
C105 Barnes, et al.1 VH3-53  (0) 12 VL2-8  (1) 11 26.1 / 134 Yes No 3.4 Å Fab-S. PDB 6XCM
B38 Wu, et al.2 VH3-53 (1) 9 VK1-9 (2) 10 117 / NA ??? ??? 1.8 Å Fab-RBD, PDB 7BZ5
CC12.3 Yuan, et al.3 VH3-53  (3) 12 VK3-20  (1) 9 20 / NA ??? ??? 2.9 Å. Fab-RBD, PDB 6XC7
Class 2: Blocks ACE2, accessibility of RBD epitope in "up"/"down" conformations
C002 this study VH3-30  (1) 17 VK1-39  (1) 9 8.9 / 37.6 Yes Yes 3.4 Å Fab-S
C104 this study VH4-34  (6) 17 VK3-20  (3) 9 23.3 / 140 Yes Yes 3.7 Å Fab-S
C119 this study VH1-46  (1) 20 VL2-14  (3) 11 9.1 / 97.8 Yes Yes 3.5 Å Fab-S
C121 this study VH1-2  (2) 22 VL2-23  (0) 10 6.7 / 22.3 Yes Yes 3.6 Å Fab-S
C144 this study VH3-53  (3) 25 VL2-14  (1) 10 6.9 / 29.7 Yes Yes 3.3 Å Fab-S
COVA2-39 Wu, et al.4 VH3-53  (3) 17 VL2-23  (1) 10 36 / NA ??? ??? 1.7 Å Fab-RBD, PDB 7JMP
5A6 Wang, et al.5 75.5 / NA Yes Yes 2.4 Å Fab-S
P2B-2F6 Ju, et al.6 VH4-38*02  (2) 20 VL2-8  (0) 10 50 / NA ??? ??? 2.9 Å Fab-RBD, PDB 7BWJ
Ab2-4 Liu, et al.7 VH1-2  (3) 15 VL2-8 (0) 10 394 / NA Yes No 3.2 Å Fab-S, PDB 6XEY
BD23 Cao, et al.8 VH7-4*02  (0) 19 VK1-5*03  (0) 9 4800 / NA No No 3.8 Å Fab-S, PDB 7BYR
Class 3: Does not overlap with ACE2 binding site, accessibility of RBD epitope in "up"/"down" conformations
C135 this study VH3-30  (4) 12 VK1-5  (3) 9 16.6 / 48.9 No No 3.5 Å Fab-S
S309 Pinto, et al.9 VH1-18  (6) 20 VK3-20  (3) 8 79* / NA No No 3.1 Å Fab-S, PDB 6WPS
C110 this study VH5-51  (2) 21 VK1-5  (3) 9 18.4 / 77.3 No No 3.8 Å Fab-S
REGN10987 Hansen, et al.10 VH3-30  (4) 13 VL2-14  (6) 10 6.1 / NA ??? ??? 3.9 Å Fab-RBD, PDB 6XDG
Class 4: Does not overlap with ACE2 binding site, accessibility of RBD epitope only in "up" conformation
CR3022 Yuan, et al.11 VH5-51  (8) 12 VK4-1  (3) 9 >10,000 / NA ??? ??? 3.1 Å Fab-RBD, PDB 6W41
COV1-16 Liu, et al.12 VH1-46 (1) 20 VK1-33 (3) 10 130 / NA ??? ??? 2.9 Å Fab-RBD
EY6A Zhou, et al.13 VH3-30*18  (3) 14 VK1-39  (0) 10 70-20,000**/ NA No Yes 3.7 Å Fab-S, PDB 6ZDH
^Average human antibody CDRH3 and CDRL3 lengths are 15 (CDRH3) and 9-10 (CDRL3) amino acids.
*IC50 calculated against authentic SARS-CoV-2 virus.
**IC50 varied depending on neutralization assay utilized.
†Unknown IC90s indicated as NA (not available).
§Potential for intra-spike crosslinking by an IgG binding to a single spike trimer was evaluated as described in the Methods.
??? Inference that cannot be made from a structure of a Fab bound to a RBD.
IGHV = Immunoglobulin heavy chain variable gene segment; 
IGLV= Immunoglobulin light chain variable gene segment
V gene segments, somatic hypermutation (SHM) information, CDR lengths, IC50/IC90 values for NAbs in this study are from ref.
14.
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 790 
Extended Data Figure 1: X-ray structure and epitope mapping of VH3-53 hNAb C102. a, X-791 
ray structure of C102 Fab – RBD331-518 complex. b, C102 CDR loops mapped on the RBD 792 
surface. b, Surface representation of C102 epitope colored by C102 HC (dark green) and LC 793 
(light green) interactions. c, CDRH1, CDRH2 and d, CDRH3 interactions with RBD residues. 794 
Potential H-bond contacts are illustrated as dashed lines. f, Left: Overlay of C102-RBD crystal 795 
structure (cartoon) with C105-S trimer cryoEM density (PDB 6XCM, EMD-22127) illustrating 796 
conserved binding to RBD epitope in an “up” conformation. Right: The C102 epitope is sterically 797 
occluded when aligned to a “down” RBD conformation (red and yellow star). SARS-CoV-2 S 798 
domains are dark gray (S2 domain) and light gray (S1 domain); the C105 Fab is yellow-green. 799 
g, Alignment of selected CDRH3 sequences for VH3-53/VH3-66 SARS-CoV-2 neutralizing 800 
antibodies (IMGT definition15). h, Overlay of hNAb COVA2-39 Fab4 (lime green and lemon, from 801 
COVA2-39-RBD structure, PDB 7JMP) and C144 Fab (blue, from C144-S structure) aligned on 802 
a RBDA of C144 epitope. COVA2-39 adopts a distinct conformation relative to the C102-like 803 
VH3-53/short CDRH3 NAb class and to C144, recognizing its RBD epitope only in an “up” RBD 804 
conformations due to steric clashes (red and yellow star) with the N343RBD-associated glycan on 805 
the adjacent RBD. i, Polyreactivity assay. IgGs were evaluated for binding to baculovirus 806 
extracts to assess non-specific binding. Polyreactive positive control IgGs were NIH45-46, 807 
NIH45-46G54W, and 45-46m2. Negative controls were bovine serum albuminn (BSA) and IgGs 808 
N6 and 3BNC117. Relative Light Unit (RLU) values are presented as the mean and standard 809 
deviation of triplicate measurements. 810 
 811 
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Extended Data Figure 2 814 
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 817 
Extended Data Figure 2. Overview of VH3-53/VH3-66 hNAb structures. a, Superimposition 818 
of VH and VL domains of C102 with other VH3-53/VH3-66 NAbs (top) and RMSD calculations 819 
(bottom). b, BSA comparisons for the indicated Fab/RBD structures. BSAs were calculated 820 
using PDBePISA16 and a 1.4 Å probe. 821 
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Extended Data Figure 3 824 
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Extended Data Figure 3. Cryo-EM data processing and validation for C144-S, C002-S, and 828 
C121-S complexes. Representative micrograph, 2D class averages, gold-standard FSC plots, 829 
and local resolution estimations for a-c, C144-S 6P, d-f, C002-S 2P, and g-I, C121-S 2P. For 830 
the C002-S dataset, two classes were resolved: State 1, C002 Fabs bound to 3 “down” RBDs, 831 
and State 2, C002 Fabs bound to 2 “down”/1 “up” RBD. For the C121-S 2P dataset, two classes 832 
were resolved: State 1, C121 Fabs bound to 2 “down”/1 “up” RBD and State 2, C121 Fabs 833 
bound to 1 “down”/2 “up” RBDs.    834 
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Extended Data Figure 4 837 
 838 
 839 
 840 
Extended Data Figure 4. Cryo-EM processing, validation, and reconstruction for C119-S 841 
and C104-S complexes. a, 3.6 Å cryo-EM reconstruction for a C119-S trimer complex. b, 3.7 Å 842 
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cryo-EM reconstruction for a C104-S trimer complex. Representative micrograph, 2D class 843 
averages, gold-standard FSC plot, and local resolution estimation for c-e, C119-S2P and, d-f, 844 
C104-S. Both complexes revealed binding of Fabs to both “down” and “up” RBD conformations.  845 
 846 
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Extended Data Figure 5 850 
 851 
 852 
Extended Data Figure 5. Primary and secondary epitopes of class 2 hNAbs.  853 
a-c, Primary epitopes for C002 (panel a), C121 (panel b), and C119 (panel c) on “down” RBD. A 854 
secondary epitope is observed if a Fab is bound to an adjacent “up” RBD for these NAbs. 855 
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Antibody paratopes are represented as cartoons. A similar interaction in the C104-S structure is 856 
not shown due to low local resolution on the “up” RBD. d-g, Primary epitopes for C119 (panel 857 
d), C104 (panel e), P2B-2F6 (panel f; PDB 7BWJ), and BD23 (panel g, PDB 7BYR). The 858 
existence of secondary epitopes for P2B-2F6 and BD23 cannot be determined because the 859 
P2B-2F6 epitope was determined from a crystal structure with an RBD6, and the BD23-S cryo-860 
EM structure showed only one bound Fab8. h, Measurement of Cα distance between the C-861 
termini of adjacent C121 CH1 domains (residue 222HC on each Fab). Measurements of this type 862 
were used to evaluate whether intra-spike crosslinking by an IgG binding to a single spike trimer 863 
was possible for hNAbs in Extended Data Table 1. 864 
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Extended Data Figure 6 866 
 867 
 868 
 869 
Extended Data Figure 6. Mapping somatic hypermutations (SHMs) of SARS-CoV-2 NAbs. 870 
a-f, Somatic hypermutations in HC and LC V gene segments for C002 (panel a), C121 (panel 871 
b), C119 (panel c), C144 (panel d), C102 (panel e) and C135 (panel f) are shown as spheres on 872 
the antibody VH and VL domains (ribbon representations). The primary RBD epitope is shown as 873 
a light gray surface; secondary RBD epitope for C144 is in dark gray.   874 
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Extended Data Figure 7 875 
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Extended Data Figure 7. Cryo-EM structure of C110-S complex and epitope mapping.  a, 879 
3.8 Å cryo-EM reconstruction of C110-S trimer complex. b, Composite model of C110-RBD 880 
(purple and gray, respectively) overlaid with the SARS-CoV-2 NAb REGN-10987 (yellow, PDB 881 
6XDG) and soluble ACE2 (green, PDB 6M0J). Model was generated by aligning structures on 882 
188 RBD Cα atoms. c-f, Surface representation of RBD epitopes for c, C135 (blue), d, S309 883 
(brown, PDB 6WSP), e, C110 (purple) and f, REGN-10987 (yellow, PDB 6XDG). Given the low 884 
resolution of the antibody-RBD interface, epitopes were assigned by selection of any RBD 885 
residue within 7 Å of any antibody Cα atom. Mutation sites found in sequence isolates17 (green) 886 
and in laboratory selection assays18 (red) are shown. Representative micrograph, 2D class 887 
averages, gold-standard FSC plot, and local resolution estimation for g-i, C135-S 2P and, j-l, 888 
C110-S 2P. Both complexes revealed binding of Fabs to both 2 “down”/1 “up” RBD 889 
conformations. 890 
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Extended Data Figure 8 893 
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 896 
Extended Data Figure 8. Possibilities for simultaneous engagement of C144 and C135 on 897 
spikes with different combinations of “up” and “down” RBDs. Modeling of C144 (light blue) 898 
and C135 (dark blue) VH-VL domains on different RBD conformations. Steric clashes are shown 899 
as a red and yellow star.  900 
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Extended Data Figure 9 901 
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 903 
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Extended Data Figure 9. SPR binding data for hNAbs.  904 
Kinetic and equilibrium constants for binding to unaltered RBD (indicated as wt) and mutant 905 
RBDs are shown in tables beside structures of a representative NAb-RBD complex for each 906 
class. Residues that were mutated are highlighted as colored sidechains on a gray RBD 907 
surface. Antibody VH-VL domains are shown as cartoons. Kinetic and equilibrium constants for 908 
NAbs that contact adjacent RBDs on S trimer (C144, C002, C119, and C121) do not account for 909 
contacts to a secondary RBD since binding was assayed by injected monomeric RBDs over 910 
immobilized IgGs. * indicates kinetic constants determined from a two-state binding model.   911 
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Extended Data Figure 10 913 
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 915 
 916 
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Extended Data Figure 10: Summary of hNAbs. a, Structural depiction of a representative 917 
NAb from each class binding its RBD epitope. b, Composite model illustrating non-overlapping 918 
epitopes of NAbs from each class bound to a RBD monomer. c, Epitopes for SARS-CoV-2 919 
NAbs. RBD residues involved in ACE2 binding are boxed in green. Diamonds represent RBD 920 
residues contacted by the indicated antibody. 921 
 922 
 923 
 924 
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